Vistagen Presents Data Showing PH80's Potential As Rapid Intranasal Treatment For Menopause Hot Flashes, At The Menopause Society 2025 Annual Meeting

Research supports the product candidate's non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkers

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented exploratory data at The Menopause Society 2025 Annual Meeting in Orlando, Florida. These findings demonstrate PH80's potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms (hot flashes) due to menopause.

The research presented by Vistagen supports PH80's ability to reduce autonomic nervous system activity after intranasal administration and noted that PH80 was not absorbed into the blood in humans. Nonclinical studies demonstrated that PH80 had no binding activity on steroid hormones or neurotransmitter receptors in vitro and had no effects on reproductive organs in laboratory mice and rats.